<DOC>
	<DOCNO>NCT00002874</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Androgens stimulate growth prostate cancer cell . Hormone therapy use bicalutamide may fight prostate cancer reduce production androgen . It yet know radiation therapy effective without bicalutamide prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without bicalutamide treat patient stage II , stage III , recurrent prostate cancer elevate PSA level follow radical prostatectomy .</brief_summary>
	<brief_title>Radiation Therapy With Without Bicalutamide Treating Patients With Stage II , Stage III , Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival follow radiotherapy without bicalutamide patient elevate prostate-specific antigen ( PSA ) evidence metastatic disease follow radical prostatectomy pathologic T3 N0 prostate cancer . - Compare regimen respect time second PSA-based progression , time distant failure , disease-specific survival , non-disease-specific survival patient population . - Compare regimen respect time third PSA failure ( PSA progression hormone therapy second PSA failure ) potential predictor impend cancer death patient . - Compare regimen respect 5-year 10-year freedom progression rate . - Compare regimen respect unintended adverse effect treatment . - Allow subsequent analysis emerge molecular pathologic predictor outcome prospective collection paraffin block radical prostatectomy specimen . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify neoadjuvant hormone therapy , surgical ( inked ) margin status , PSA nadir surgery , PSA level entry , participate center . All patient undergo radiotherapy original prostate volume , tumor resection bed , proximal membranous urethra 7.2 week . Beginning immediately upon prior initiation radiotherapy , patient randomize receive either bicalutamide placebo daily 2 year . Recommended treatment patient increase PSA bone metastases consist maximal androgen blockage combination orchiectomy LHRH analogue plus bicalutamide flutamide . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 810 patient accrue study within approximately 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Carcinoma prostate pathologic stage T3 N0 pT2 pN0 positive inked resection margin least 12 week prior study entry Radical prostatectomy ( retropubic perineal ) pelvic lymphadenectomy ( open laparoscopic ) require least 16 week prior entry No persistent urinary extravasation surgery Suitable radiotherapy hormonal therapy determine radiation oncologist urologist No metastasis postprostatectomy radioisotope bone scan within 16 week prior entry Pathologic stage T2 without positive margin pathologic N0 prostatic fossa/anastamosis biopsy time rise PSA document recurrent cancer allow PSA 0.24.0 ng/mL study entry No distant metastases PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 80100 % Life expectancy : More 10 year Hematopoietic : White blood cell count ( WBC ) least 4,000/mm^3 Platelet count least 100,000/mm^3 Hematocrit least 36 % Hemoglobin least 10 g/dL Hepatic : Bilirubin normal Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2.5 time normal Renal : Creatinine great 2 time normal Other : No malignancy within past 5 year except basal squamous cell skin cancer adequately treat invasive cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy prostate cancer Chemotherapy : No prior chemotherapy prostate cancer Endocrine therapy : No prior adjuvant hormonal therapy Prior neoadjuvant hormonal therapy allow Radiotherapy : No prior radiotherapy prostate cancer Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>